Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC).

JE Rosenberg, SS Sridhar, J Zhang, DC Smith… - 2018 - ascopubs.org
4504 Background: Patients (pts) with mUC are in need of novel therapies. Enfortumab
vedotin (EV) is an antibody–drug conjugate that delivers a microtubule-disrupting agent to …
被引用次数：44 相关文章

[引用][C] Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC)

JE Rosenberg, SS Sridhar, J Zhang… - Journal of clinical …, 2018 - scholarship.miami.edu